Inflammation-related prognostic markers in resected hepatocellular carcinoma
Hepatocellular carcinoma is usually detected late and therapeutic options are unsatisfactory. Despite marked progress in patient care, HCC remains among the deadliest cancers world-wide. While surgical resection remains a key option for early-stage HCC, the 5-year survival rates after surgical resec...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1267870/full |
| _version_ | 1797400713813295104 |
|---|---|
| author | Fabio Giannone Fabio Giannone Fabio Giannone Nevena Slovic Patrick Pessaux Patrick Pessaux Patrick Pessaux Catherine Schuster Thomas F. Baumert Thomas F. Baumert Thomas F. Baumert Thomas F. Baumert Joachim Lupberger |
| author_facet | Fabio Giannone Fabio Giannone Fabio Giannone Nevena Slovic Patrick Pessaux Patrick Pessaux Patrick Pessaux Catherine Schuster Thomas F. Baumert Thomas F. Baumert Thomas F. Baumert Thomas F. Baumert Joachim Lupberger |
| author_sort | Fabio Giannone |
| collection | DOAJ |
| description | Hepatocellular carcinoma is usually detected late and therapeutic options are unsatisfactory. Despite marked progress in patient care, HCC remains among the deadliest cancers world-wide. While surgical resection remains a key option for early-stage HCC, the 5-year survival rates after surgical resection are limited. One reason for limited outcomes is the lack of reliable prognostic biomarkers to predict HCC recurrence. HCC prognosis has been shown to correlate with different systemic and pathological markers which are associated with patient survival and HCC recurrence. Liver inflammatory processes offer a large variety of systemic and pathological markers which may be exploited to improve the reliability of prognosis and decision making of liver surgeons and hepatologists. The following review aims to dissect the potential tools, targets and prognostic meaning of inflammatory markers in patients with resectable HCC. We analyze changes in circulant cellular populations and assess inflammatory biomarkers as a surrogate of impaired outcomes and provide an overview on predictive gene expression signatures including inflammatory transcriptional patterns, which are representative of poor survival in these patients. |
| first_indexed | 2024-03-09T01:58:31Z |
| format | Article |
| id | doaj.art-3da65f9bf57d4dee8f93e38e26ed7434 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-09T01:58:31Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3da65f9bf57d4dee8f93e38e26ed74342023-12-08T07:51:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-12-011310.3389/fonc.2023.12678701267870Inflammation-related prognostic markers in resected hepatocellular carcinomaFabio Giannone0Fabio Giannone1Fabio Giannone2Nevena Slovic3Patrick Pessaux4Patrick Pessaux5Patrick Pessaux6Catherine Schuster7Thomas F. Baumert8Thomas F. Baumert9Thomas F. Baumert10Thomas F. Baumert11Joachim Lupberger12Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques Unité Mixte de Recherche (UMR)_S1110, Strasbourg, FranceUnité de Chirurgie Hépato-Biliaire et Pancréatique, Service de Chirurgie Viscérale and Digestive, Hôpitaux Universitaires de Strasbourg, Strasbourg, FranceInstitut Hospitalo-Universitaire (IHU), Strasbourg, FranceUniversité de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques Unité Mixte de Recherche (UMR)_S1110, Strasbourg, FranceUniversité de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques Unité Mixte de Recherche (UMR)_S1110, Strasbourg, FranceUnité de Chirurgie Hépato-Biliaire et Pancréatique, Service de Chirurgie Viscérale and Digestive, Hôpitaux Universitaires de Strasbourg, Strasbourg, FranceInstitut Hospitalo-Universitaire (IHU), Strasbourg, FranceUniversité de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques Unité Mixte de Recherche (UMR)_S1110, Strasbourg, FranceUniversité de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques Unité Mixte de Recherche (UMR)_S1110, Strasbourg, FranceInstitut Hospitalo-Universitaire (IHU), Strasbourg, FranceService d’hépato-gastroentérologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, FranceInstitut Universitaire de France (IUF), Paris, FranceUniversité de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques Unité Mixte de Recherche (UMR)_S1110, Strasbourg, FranceHepatocellular carcinoma is usually detected late and therapeutic options are unsatisfactory. Despite marked progress in patient care, HCC remains among the deadliest cancers world-wide. While surgical resection remains a key option for early-stage HCC, the 5-year survival rates after surgical resection are limited. One reason for limited outcomes is the lack of reliable prognostic biomarkers to predict HCC recurrence. HCC prognosis has been shown to correlate with different systemic and pathological markers which are associated with patient survival and HCC recurrence. Liver inflammatory processes offer a large variety of systemic and pathological markers which may be exploited to improve the reliability of prognosis and decision making of liver surgeons and hepatologists. The following review aims to dissect the potential tools, targets and prognostic meaning of inflammatory markers in patients with resectable HCC. We analyze changes in circulant cellular populations and assess inflammatory biomarkers as a surrogate of impaired outcomes and provide an overview on predictive gene expression signatures including inflammatory transcriptional patterns, which are representative of poor survival in these patients.https://www.frontiersin.org/articles/10.3389/fonc.2023.1267870/fullHCCbiomarkersgenetic signaturesinflammationpatient outcome |
| spellingShingle | Fabio Giannone Fabio Giannone Fabio Giannone Nevena Slovic Patrick Pessaux Patrick Pessaux Patrick Pessaux Catherine Schuster Thomas F. Baumert Thomas F. Baumert Thomas F. Baumert Thomas F. Baumert Joachim Lupberger Inflammation-related prognostic markers in resected hepatocellular carcinoma Frontiers in Oncology HCC biomarkers genetic signatures inflammation patient outcome |
| title | Inflammation-related prognostic markers in resected hepatocellular carcinoma |
| title_full | Inflammation-related prognostic markers in resected hepatocellular carcinoma |
| title_fullStr | Inflammation-related prognostic markers in resected hepatocellular carcinoma |
| title_full_unstemmed | Inflammation-related prognostic markers in resected hepatocellular carcinoma |
| title_short | Inflammation-related prognostic markers in resected hepatocellular carcinoma |
| title_sort | inflammation related prognostic markers in resected hepatocellular carcinoma |
| topic | HCC biomarkers genetic signatures inflammation patient outcome |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1267870/full |
| work_keys_str_mv | AT fabiogiannone inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT fabiogiannone inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT fabiogiannone inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT nevenaslovic inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT patrickpessaux inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT patrickpessaux inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT patrickpessaux inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT catherineschuster inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT thomasfbaumert inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT thomasfbaumert inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT thomasfbaumert inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT thomasfbaumert inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma AT joachimlupberger inflammationrelatedprognosticmarkersinresectedhepatocellularcarcinoma |